Bleeding risks appear to track with greater CMB burden, but validation studies are needed.
A recent ischemic stroke and documented atrial fibrillation (Afib) typically constitute a strong indication for anticoagulation, but reports suggesting a potential link between cerebral microbleeds (CMBs) and risk for intracerebral hemorrhage (ICH) have given some clinicians pause. Although a reduction in secondary ischemic strokes with anticoagulation for atrial fibrillation is well established, a better understanding of whether the bleeding risks for specific patients might outweigh benefits could change management in some cases.
In this systematic review and meta-analysis, investigators identified all reported cohort studies with at least 6 months of follow-up that included >50 ischemic stroke patients treated with oral anticoagulation fo…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Neurological Disorders and Stroke; NIH/National Center for Advancing Translational Sciences
DisclosuresGrant/Research SupportNIH/National Institute of Neurological Disorders and Stroke; NIH/National Center for Advancing Translational Sciences